LISATA THERAPEUTICS INC

LSTANASDAQ

🏆 #3925 by market capEarnings Nov 5US Equity

$1.21▲ $0.13 (+11.01%)

🌙 After hours$1.21▲ 0.00%Regular close · extended-hours price shown

1h—

24h▲ 11.0%

7d▲ 8.0%

14d▲ 10.0%

30d▼ 67.4%

1y▼ 56.2%

🏦Market Cap

$11M

Small Cap

📈Revenue Growth (YoY)

-27.1%

Declining

📊Gross Margin

9.5%

Thin

💵FCF Margin

2641.2%

Strong

⚖️P/S Ratio

56.5x

Expensive

Otter Score

Weak

Trading Snapshot

Day Range: $1.19 – $1.22
52-Week Range: $0.99 – $5.07
Volume: $1.68B
Avg Volume: $1.42B
Shares Outstanding: 9.1M
Next Earnings: Oct 13, 2026

Fundamentals Snapshot

Annual Revenue: $170,000
Last Q Revenue: $43,366
P/E Ratio: —
P/S Ratio: 56.5x
EPS (TTM): $-1.91
Dividend Yield: —

Why Investors Own LSTA

✓High-growth profile — revenue up +29.6% YoY with expanding US Equity exposure.
✓Healthy economics — 45% gross margin and 24% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)

$170,000▲ +34.6% YoY

Gross Margin (TTM)

45.3%▲ +0.4% YoY

Operating Income (TTM)

$46,750▲ +34.6% YoY

Free Cash Flow (TTM)

$40,460▲ +34.6% YoY

About LISATA THERAPEUTICS INC

Lisata Therapeutics, Inc. is a clinical-stage biopharmaceutical firm focused on pioneering and bringing to market cellular therapies. These treatments are designed to either reverse disease progression or facilitate the repair of damaged bodily tissues. The company's product portfolio features several notable candidates: HONEDRA, which has received SAKIGAKE designation and is presently in Phase II clinical trials for critical limb ischemia; XOWNA, currently undergoing Phase IIb testing for coronary microvascular dysfunction; and CLBS201, a CD34+ cell therapy aimed at individuals with chronic kidney disease who are not yet on dialysis. Founded in 1980 and based in Basking Ridge, New Jersey, the company was initially known as NeoStem, Inc., then rebranded as Caladrius Biosciences, Inc. in June 2015, before assuming its present identity as Lisata Therapeutics, Inc. on September 15, 2022.

🦦